
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics Inc has exhibited robust growth in Chromium reaction volumes, indicating a strong market demand for its integrated solutions amid challenging conditions in the pharmaceutical sector. The company's consumables are projected to experience significant growth, with anticipated increases ranging from 5 to 19 times by 2027, outpacing revenue growth from instruments. This trend suggests a solid foundation for the company's financial performance, reflecting the ongoing alignment of its offerings with the complexities of biological systems.
Bears say
10x Genomics has experienced a significant contraction in its market performance, with double-digit pricing pressures and flat to declining volumes expected to persist until 2027. The company reported weaker-than-anticipated fourth-quarter earnings, with a miss in earnings per share and a full-year revenue outlook that fell below expectations. Furthermore, despite some growth in its market segments since the stock's peak in 2021, the expansion has not met analyst projections, contributing to a decline of over 90% in the stock price from its previous highs.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares